

# PRV

PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen

10/562302

IAP17 Rec'd PCT/PTO 22 DEC 2005

Intyg  
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande  
Applicant

St Jude Medical AB Järfälla SE,  
Torpo Maria Sundbyberg SE,  
Öhlander Malin Stockholm SE,  
Björling Anders Järfälla SE,  
Ljungström Karin Hässelby SE

(81) Designerade stater AP: all, AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
Designated states BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE,  
DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LI, LK, LR, LS, LT, LU, LV,  
MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,  
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


(21) Patentansökningsnummer PCT SE04/00698  
Patent application number

(86) Ingivningsdatum 2004-05-06  
Date of filing

CERTIFIED COPY OF  
PRIORITY DOCUMENT

Stockholm, 2005-09-09

För Patent- och registreringsverket  
For the Patent- and Registration Office

  
Görel Gustafsson

Avgift  
Fee 170:-

**PCT REQUEST**

Original (for SUBMISSION )

0	<b>For receiving Office use only</b>	
0-1	International Application No.	<b>PCT / SE 2004 / 0 0 0 6 9 8</b>
0-2	International Filing Date	<b>0 6 -05- 2004</b>
0-3	Name of receiving Office and "PCT International Application"	<b>The Swedish Patent Office PCT International Application</b>
0-4	<b>Form - PCT/RO/101 PCT Request</b>	
0-4-1	Prepared Using	<b>PCT-SAFE [EASY mode] Version 3.50 (Build 0002.162)</b>
0-5	<b>Petition</b>  The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	<b>Swedish Patent Office (RO/SE)</b>
0-7	Applicant's or agent's file reference	<b>P 04-128NH</b>
I	Title of Invention	<b>DETECTION OF DIASTOLIC HEART FAILURE</b>
II	<b>Applicant</b>	
II-1	This person is:	<b>applicant only</b>
II-2	Applicant for	<b>all designated States except US</b>
II-4	Name:	<b>ST. JUDE MEDICAL AB</b>
II-5	Address:	<b>S-175 84 JÄRFÄLLA Sweden</b>
II-6	State of nationality	<b>SE</b>
II-7	State of residence	<b>SE</b>
III-1	<b>Applicant and/or inventor</b>	
III-1-1	This person is:	<b>applicant and inventor</b>
III-1-2	Applicant for	<b>US only</b>
III-1-4	Name (LAST, First)	<b>TORPO, Maria</b>
III-1-5	Address:	<b>Duvkullavägen 42B, 2 tr S-172 37 SUNDBYBERG Sweden</b>
III-1-6	State of nationality	<b>SE</b>
III-1-7	State of residence	<b>SE</b>

P 04-128NH

2/4

**PCT REQUEST**

Original (for SUBMISSION )

III-2	<b>Applicant and/or inventor</b>	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	ÖHLANDER, Malin
III-2-5	Address:	Mariatorget 6a, 3 trög S-118 48 STOCKHOLM Sweden
III-2-6	State of nationality	SE
III-2-7	State of residence	SE
III-3	<b>Applicant and/or inventor</b>	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	BJÖRLING, Anders
III-3-5	Address:	Handbollvägen 24G S-175 53 JÄRFÄLLA Sweden
III-3-6	State of nationality	SE
III-3-7	State of residence	SE
III-4	<b>Applicant and/or inventor</b>	
III-4-1	This person is:	applicant and inventor
III-4-2	Applicant for	US only
III-4-4	Name (LAST, First)	LJUNGSTRÖM, Karin
III-4-5	Address:	Albert Landbergs gränd 34 S-165 70 HÄsselby Sweden
III-4-6	State of nationality	SE
III-4-7	State of residence	SE
IV-1	<b>Agent or common representative; or address for correspondence</b>	
The person identified below is hereby/ has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:		
IV-1-1	Name:	GROTH & Co. KB
IV-1-2	Address:	GROTH & Co. KB Box 6107 S-102 32 STOCKHOLM Sweden
IV-1-3	Telephone No.	+46 8 729 91 00
IV-1-4	Facsimile No.	+46 8 31 67 67
IV-1-5	e-mail	info@groth.se
IV-2	Additional agent(s)	additional agent(s) with same address as

P 04-128NH

3/4

**PCT REQUEST**

Original (for SUBMISSION )

IV-2-1	Name(s)	first named agent HOPFGARTEN, Nils; KARLSSON, Leif; EMTEDAL, Artur; JOHANSSON WEBJÖRN, Ingmari; ASKERBERG, Fredrik; THEANDER, Anna; LÖFGREN, Håkan; AXELSSON, Nils Åke; KÄRN, Ulf; LINDBLOM, Erik J	
V	<b>DESIGNATIONS</b>		
V-1	The filing of this request constitutes under Rule 4.9(a), the designation of all Contracting States bound by the PCT on the international filing date, for the grant of every kind of protection available and, where applicable, for the grant of both regional and national patents.		
VI-1	Priority Claim	NONE	
VII-1	International Searching Authority Chosen	Swedish Patent Office (ISA/SE)	
VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	<b>Check list</b>	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	4 ✓	✓
IX-2	Description	7 ✓	-
IX-3	Claims	4 ✓	-
IX-4	Abstract	1 ✓	✓
IX-5	Drawings	4 ✓	-
IX-7	<b>TOTAL</b>	20 ✓	
IX-8	Accompanying Items	paper document(s) attached	electronic file(s) attached
IX-17	Fee calculation sheet	✓	-
IX-17	PCT-SAFE physical media	-	✓
IX-19	Figure of the drawings which should accompany the abstract	1	
IX-20	Language of filing of the international application	English	

P 04-128NH

4/4

**PCT REQUEST**

Original (for SUBMISSION )

X-1	Signature of applicant, agent or common representative	
X-1-1	Name (LAST, First)	HOPFGARTEN, Nils
X-1-2	Name of signatory	
X-1-3	Capacity	

**FOR RECEIVING OFFICE USE ONLY**

10-1	Date of actual receipt of the purported international application	06 -05- 2004
10-2	Drawings:	
10-2-1	Received <input checked="" type="checkbox"/>	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/SE
10-6	Transmittal of search copy delayed until search fee is paid	

**FOR INTERNATIONAL BUREAU USE ONLY**

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

**PCT (ANNEX - FEE CALCULATION SHEET)**

Original (for SUBMISSION )

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only	<b>PCT / SE 2004 / 0 0 0 6 9 8</b>
0-1	International Application No.	
0-2	Date stamp of the receiving Office	<b>0 6 -05- 2004</b>

0-4	Form PCT/RO/101 (Annex) PCT Fee Calculation Sheet Prepared Using	PCT-SAFE [EASY mode] Version 3.50 (Build 0002.162)		
0-9	Applicant's or agent's file reference	<b>P 04-128NH</b>		
2	Applicant	<b>ST. JUDE MEDICAL AB</b>		
12	Calculation of prescribed fees	fee amount/multiplier	Total amounts (SEK)	
12-1	Transmittal fee	T	1200	1200
12-2-1	Search fee	S	13870	18870
12-2-2	International search to be carried out by	SE		
12-3	International filing fee (first 30 sheets)	i1	8140	
12-4	Remaining sheets	0		
12-5	Additional amount	(X) 0		
12-6	Total additional amount	i2	0	
12-7	i1 + i2 =	i	8140	
12-12	EASY Filing reduction	R	-580	
12-13	Total International filing fee (i-R)	I	7560	7560
12-14	Fee for priority document  Number of priority documents requested	0		
12-15	Fee per document	(X) 0		
12-16	Total priority document fee:	P		
12-17	<b>TOTAL FEES PAYABLE (T+S+I+P)</b>		22630	22630
12-19	Mode of payment	cheque		

An implantable medical apparatus for detecting diastolic heart failure, DHF, comprises a DHF determining device for determining at least one DHF parameter for detecting a DHF state of the heart of a patient. The DHF determining device comprises a means for determining, as said DHF parameter, the time length (DT,IVRT) of a predetermined phase of diastole. A pacemaker comprises such an apparatus and control means for optimising pacing therapy and pacemaker settings depending on the determined time length. A corresponding method of detecting diastolic heart failure, DHF, comprises the step of determining at least one DHF parameter for detecting DHF state of the heart of a patient. This step comprises determining, as said DHF parameter, the time length (DT,IVRT) of a predetermined phase of diastole.

10/562302

DETECTION OF DIASTOLIC HEART FAILURE

IAP17 Rec'd PCT/PTO 22 DEC 2005

Technical Field

The present invention relates to an implantable medical apparatus for  
5 detecting diastolic heart failure, DHF, comprising a DHF determining device for  
determining at least one DHF parameter for detecting a DHF state of the heart of a  
patient. The invention also relates to a pacemaker having such an apparatus, and a  
method for detecting diastolic heart failure, DHF, comprising the step of determining  
at least one DHF parameter for detecting a DHF state.

10

Background

There is a growing recognition that congestive heart failure caused by a  
predominant abnormality in the diastolic function, i.e. diastolic heart failure, DHF, is  
both common and causes significant morbidity and mortality. Therefore early  
15 detection of DHF is important such that a suitable treatment can be started. Patients  
do not, however, seem to have symptoms at an early stage. In addition it has been  
hard to separate diastolic and systolic heart failure and they may also exist  
simultaneously.

The time progress of different phases of diastole of a patient suffering from  
20 DHF is changed vis-à-vis that of a healthy person, see Michael R. Zile and Dirk L.  
Brusaert, "New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part  
I", Circulation 2002; 105: 1387. Thus DHF can be divided into three phases, see  
figure 1. Figure 1a shows left atrial pressure, LA dotted line, and left ventricular  
pressure, LV solid line, as functions of time for a normal, healthy state and for three  
25 phases of DHF. The first phase of DHF is referred to as "Impaired Relaxation". In  
this phase characteristic times related to relaxation and filling of the left ventricle is  
prolonged compared to corresponding times of a normal heart. After this phase the  
disease progresses into a phase called "Pseudonormal". In this phase the heart  
compensates and the characteristic times returns to more normal values, close to  
30 those of the normal heart. This phase is followed by the final phase of DHF called  
"Restrictive". In the final phase the characteristic times are shorter than for the  
normal heart. Figure 1b shows corresponding measured mitral blood flow velocities.  
Letter "E" denotes the so-called E-wave, early filling of the ventricle, and "A" the A-  
wave, contribution from the atrium during its contraction.

The purpose of the present invention is to utilize these changes in time during diastole of patients suffering from DHF for proposing a technique for DHF detection.

#### Disclosure of the Invention

5 This purpose is obtained by an apparatus, a pacemaker and a method of the kind mentioned in the introductory portion of the description and having the characterizing features of claims 1, 17 and 18 respectively.

Thus with the present invention early detection of DHF is possible and it is also possible to detect how the disease progresses. Even the beginning of a DHF of  
10 a healthy person can be detected.

According to advantageous embodiments of the apparatus according to the invention the DHF determining device comprises sensor and calculating means for determining the time, DT, from the occurrence of peak blood flow velocity through the mitral valve to zero blood flow velocity therethrough as said DHF parameter. The  
15 sensor and calculating means are adapted to determine DT by extrapolating the mitral blood flow velocity to zero, if zero velocity is not obtained before atrial contraction. The sensor and calculating means are then preferably adapted to determine the time derivative of the blood flow velocity through the mitral valve shortly after said peak blood flow velocity for use for linearly extrapolating the blood  
20 flow velocity to zero. DT denotes the E-wave deceleration time or "Dec time" related to the early filling of the left ventricle as mentioned above. If zero velocity is not obtained due to the atrial contraction, so-called A-wave influence, which will be described more in detail below. DT can consequently be determined by extrapolation in such situations.

25 According to still another advantageous embodiment of the apparatus according to the invention the DHF determining device comprises sensor and calculating means for determining isovolumic relaxation time, IVRT, i.e. the time from the closing of the aortic valve to the opening of the mitralis valve, as said DHF parameter.

30 According to yet other advantageous embodiments of the apparatus according to the invention the sensor and calculating means comprise a means for measuring IEGM or a means for measuring an impedance in the patient's heart or a sound sensor or an accelerometer, intended to be placed on the left ventricle of the patient's heart, for determining DT and/or IVRT. Thus e.g. IVRT can be

determined from impedance measurements between the left and right ventricles, or possibly between the left ventricle and right atrium. Since there is no change in the blood volume between electrodes located as indicated above during IVRT the impedance will be substantially constant. IVRT can consequently be identified as a  
5        "still" period in the impedance after systole. IVRT can also be determined by an accelerometer positioned on the left ventricle, for instance in one of the coronary veins running on the outside of the left ventricle. IVRT is then determined by the time the ventricle is still after systole, since the ventricle is still during IVRT. No blood enters or leaves the ventricle during this phase of the cardiac cycle, only a  
10      redistribution of the pressure takes place within the ventricle without change of volume of the ventricle. DT can be determined by e.g. listening to the blood flow through the mitralis valve. The blood velocity is correlated to the frequency of the heart sound signal, its derivative corresponds to the acceleration of the blood, and DT is calculated therefrom.

15        According to other advantageous embodiments of the apparatus according to the invention the DHF determining device is adapted to determine the time length at predetermined time intervals and a storing means is provided for storing said determined time lengths. The DHF determining device can alternatively be adapted to determine changes in said time length and a storing means be provided for  
20      storing the determined changes in time length. During the follow-up of the patient stored parameters are downloaded from the storing means and evaluated by the physician for studying the progression of the disease. It is also possible to provide an alerting means to be triggered if deviations of the determined time length from predetermined limit values exceed a predetermined threshold value, or a change in  
25      the determined time length exceeds a predetermined threshold value. Thus in response to the detection of a change in the DHF parameter indicating that the patient is developing DHF or the patient is progressing into a new phase of DHF an alert can be sent calling for a follow-up by a physician.

The invention also relates to a pacemaker provided with the apparatus for  
30      detecting DHF and control means for optimising pacing therapy and pacemaker settings depending on the determined time length, as well as a method of detecting DHF.

Brief Description of the Drawings

To explain the invention in greater detail embodiments of the invention will now be described with reference to the drawings on which figure 1a and b shows left ventricular and left atrial pressures and mitral blood flow velocity respectively for a 5 normal heart and for three phases of DHF, figures 2 – 4 illustrate impedance measurements for determining IVRT in three embodiments of the invention, figure 5 illustrates an embodiment of the invention comprising special sensors for DT and IVRT determination, and figure 6 is a diagram illustrating when DT and IVRT values are stored for later evaluation and when a DHF alert is sent according to an 10 exemplifying embodiment of the invention.

Description of Preferred Embodiments

Figure 1a shows left ventricular pressure, LV Press solid line, and left atrial pressure, LA Press dotted line, during diastole and figure 1b corresponding mitral 15 Doppler left ventricular blood inflow, as measured by echocardiography, for a normal healthy heart and for three phases of diastole. Normal diastolic function is characterized by a predominant early diastolic mitral flow, E-wave, exceeding the velocity of left ventricular filling contributed by atrial contraction, A-wave in the figure. With impaired relaxation atrial contraction contributes relatively more to 20 ventricular filling, viz. A-wave > E-wave, with prolonged deceleration of the E-wave, usually > 240 msec. This phase of DHF "Impaired Relaxation" is common with increasing age and may identify patients at risk for DHF. When ventricular diastolic pressure increases to the point where atrial contraction contributes little to the filling, the E-wave again becomes predominant but with rapid deceleration, first in a 25 "Pseudonormal" pattern and ultimately in a "Restrictive" pattern, characterized by a high E-wave velocity of usually more than twice the A-wave velocity.

One of the time lengths which can be used to indicate the progress of DHF is the E-wave deceleration time, DT "Dec. Time", see figure 1b. DT is defined as the time length from the point of blood peak velocity through the mitral valve to the point 30 of zero velocity, cf. figure 1b. If zero velocity is not reached due to the A-wave influence, DT is calculated by extrapolation as illustrated in figure 1b for the phase "Impaired Relaxation". The time derivative of the flow velocity through the mitral valve shortly after the blood flow peak velocity is determined for use for linearly

extrapolating the blood flow velocity to zero. By measuring DT the beginning of a DHF and its progress can be detected.

The progress of DHF can be divided into three phases as mentioned above and each of these phases causes a change in DT, see figure 1b. The first phase of 5 DHF is referred to as "Impaired Relaxation". During this phase DT is much longer than in a normal heart. After this phase the disease progresses into a phase called "Pseudonormal". In this phase the heart compensates and DT returns to more normal values, close to the DT value of a normal heart. This phase is followed by the final stage of DHF called "Restrictive" In this phase DT is shorter than DT of a 10 normal healthy heart.

Another time length which can be used to indicate the progress of DHF is the isovolumic relaxation time, IVRT, as mentioned above. In the "Impaired Relaxation" phase of diastole IVRT is longer than for a healthy heart, as appears from figure 1b. In the "Pseudonormal" phase the heart is compensating and IVRT 15 returns to more normal values. In the final "Restrictive" phase IVRT is decreased to a shorter value than IVRT of the normal heart, cf. figure 1b.

A pacemaker according to the invention will preferably use its sensors for determining IEGMs or impedance measurements for measuring and calculating DT or IVRT at given time intervals, as will be described in further details below, and 20 either store DT or IVRT or changes in DT or IVRT in the memory of the pacemaker. In the follow-up the development of DT or IVRT over time is downloaded from the pacemaker and the physician can evaluate the results and study the progression or regression of the disease.

An alerting means can also be provided to send an alert, calling for a follow-up 25 for the patient in question, in response to the detection of a change in DT or IVRT indicating that the patient is developing DHF or the patient is progressing into a new phase of DHF.

IVRT is initiated by the closing of the aortic valve and terminated by the opening of the mitral valve. To determine when the aortic and mitral valves closes 30 and opens respectively impedance measurements or some kind of sensor can be used. Figure 2 illustrates an example of impedance measurements between left and right ventricles 1, 3. A current is supplied between the pacemaker case, schematically shown at 2, and the tip electrode 4 of a right ventricular lead 6, and

the resulting voltage is measured between the ring electrode 8 of the ventricular lead 6 and the tip electrode 10 of a unipolar coronary sinus lead 12.

Figure 3 illustrates an example wherein current is fed between the ring electrode 14 of a bipolar right atrial lead 16 and the ring electrode 20 of a bipolar coronary sinus lead 18, and the resulting voltage is measured between the tip electrodes 22 and 24 of the right atrial lead 16 and the coronary sinus lead 18 respectively.

Figure 4 illustrates still another embodiment wherein current is supplied between the tip electrode 26 of a bipolar right ventricular lead 28 and the ring electrode 30 of a bipolar coronary sinus lead 32, and the resulting voltage is measured between the ring electrode 34 of the right ventricular lead 28 and the tip electrode 36 of the coronary sinus lead 32.

Since there is practically no change in the blood volume during IVRT between the electrodes used in the embodiments illustrated above, the impedance measured in this way is substantially constant. IVRT can consequently be identified as the "still" period in the impedance after systole.

Figure 5 illustrates an embodiment wherein a special sensor 38 is used. This sensor can be of a kind which picks up noise or registers mechanical events, such as for instance a so-called CMES-sensor, cardiac mechanical sensor,. The CMES-sensor is a piezoelectric sensor the output signal of which contains a. o. pressure information. This information comprises several components, and in a certain frequency range the sensor is sensible to noise, i.e. it works as a microphone. The signal from the sensor comprises also the true pressure and its derivative. By suitable filtering of the sensor signal valve openings and closings can be detected.

The sensor 38 in figure 5 can alternatively comprise an accelerometer positioned on the left ventricle, for instance in one of the coronary veins running on the outside of the left ventricle, as shown in the figure. IVRT is then detected as the time when the ventricle is still after systole. During this time no blood leaves or enters the ventricle which consequently does not change volume.

DT can be determined in an analogous way by impedance measurements or by noise measurements with the aid of a microphone positioned in a coronary vein as illustrated in figure 5, or positioned in the right ventricular apex. DT can also

be determined by an accelerometer positioned on the outside of the left side of the heart, i.e. in the coronary sinus.

The time length used as parameter for detection of DHF can also be determined by more than one of the above described techniques.

5       Typical values of IVRT of a healthy person are 70 – 90 msec depending on age and other parameters, and typical values of DT of a healthy person are 160 – 240 msec. IVRT and DT values above 90 and 240 msec respectively are assumed to characterize a state of impaired relaxation, and values below 70 and 160 msec respectively are characterizing the restrictive phase of DHF. Thus an increase or  
10 decrease of IVRT and DT above or below the above mentioned limit values are indications of DHF and should therefore call for attention. This is illustrated in figure 6 which shows that time length values within the normal range are not stored, whereas time length values above or below the prescribed limit values are stored together with their times of occurrence. These measured time length values outside  
15 the normal range can also be triggering an alert.

The amount of deviation of the measured time lengths above or below their respective limit values is an indication of the severity of the DHF.

Thus, if the IVRT and DT values fall outside their respective normal ranges these values are stored together with the amounts by which the time lengths exceed  
20 or are below the respective limit. Possible erroneous measurement values are filtered out, such that single or very few time length values outside the normal ranges should not result in a DHF detection, and not trigger a possible alert.

## CLAIMS

1. An implantable medical apparatus for detecting diastolic heart failure, DHF, comprising a DHF determining device for determining at least one DHF parameter for detecting a DHF state of the heart of a patient, **characterized in** that said DHF determining device comprises a means (2, 4, 8, 10; 14, 20, 22, 24; 26, 30, 34, 36; 38) for determining, as said DHF parameter, the time length of a predetermined phase of diastole.
- 10 2. The apparatus according to claim 1, **characterized in** that comparison means are provided to compare said time length with predetermined upper and lower limit values for the detection of DHF.
- 15 3. The apparatus according to claims 1 or 2, **characterized in** that said DHF determining device comprises sensor and calculating means (2, 4, 8, 10; 14, 20, 22, 24; 26, 30, 34, 36; 38) for determining the time, DT, from the occurrence of peak blood flow velocity (E) through the mitral valve to zero blood flow velocity therethrough as said DHF parameter.
- 20 4. The apparatus according to claim 3, **characterized in** that said sensor and calculating means are adapted to determine DT by extrapolating the mitral blood flow velocity to zero, if zero velocity is not obtained before atrial contraction.
- 25 5. The apparatus according to claim 4, **characterized in** that said sensor and calculating means are adapted to determine the time derivative of the blood flow velocity through the mitral valve shortly after said peak blood flow velocity (E) for use for linearly extrapolating the blood flow velocity to zero.
- 30 6. The apparatus according to claim 1 or 2, **characterized in** that said DHF determining device comprises sensor and calculating means (2, 4, 8, 10; 14, 20, 22, 24; 26, 30, 34, 36; 38) for determining isovolumic relaxation time, IVRT, as said DHF parameter.

7. The apparatus according to any of the claims 3 - 6, **characterized in** that said sensor and calculating means comprise a means for measuring IEGM for determining DT and/or IVRT.
- 5 8. The apparatus according to any of the claims 3 - 6, **characterized in** that said sensor and calculating means comprise a means (2, 4, 6, 8, 10, 12; 14, 16, 18, 20, 22, 24; 26, 28, 30, 32, 34, 36) for measuring an impedance in the patient 's heart for determining DT and/or IVRT.
- 10 9. The apparatus according to any of the claims 3 - 6, **characterized in** that said sensor and calculating means comprise a sound sensor (38) for determining DT and/or IVRT.
- 15 10. The apparatus according to any of the claims 3 - 6, **characterized in** that said sensor and calculating means comprise an accelerometer (38), intended to be placed on the left ventricle of the patient 's heart, for determining DT and/or IVRT.
- 20 11. The apparatus according to any of the preceding claims, **characterized in** that said DHF determining device is adapted to determine said time length at predetermined time intervals and in that a storing means is provided for storing said determined time lengths.
- 25 12. The apparatus according to any of the claims 2 - 11, **characterized in** that said comparison means are connected to said storing means for storing said time length values above said upper limit and below said lower limit values together with the magnitudes of the deviations from corresponding limit values and the times of the occurrence of the deviated values.
- 30 13. The apparatus according to any of the claims 1 – 10, **characterized in** that said DHF determining device is adapted to determine changes in said time length and in that a storing means is provided for storing said determined changes in time length.
14. The apparatus according to any of the claims 2 – 10, **characterized in** that

an alerting means is provided to be triggered if deviation of the determined time length from said upper or lower limit values exceed a predetermined threshold value.

5 15. The apparatus according to claim 14, **characterized in** that said alerting means is adapted to be triggered if said time lengths exceed said upper or are below said lower limit for a time period of predetermined length.

10 16. The apparatus according to any of the claims 1 - 14, **characterized in** that an alerting means is provided to be triggered in response to the detection of a change in said determined time length exceeding a predetermined threshold value.

15 17. A pacemaker, **characterized in** that it comprises an apparatus according to any one of the preceding claims and control means for optimising pacing therapy and pacemaker settings depending on the determined time length.

20 18. A method of detecting diastolic heart failure, DHF, comprising the step of determining at least one DHF parameter for detecting a DHF state of the heart of a patient, **characterized in** that said step of determining at least one DHF parameter comprises determining, as said DHF parameter, the time length of a predetermined phase of diastole.

25 19. The method according to claim 18, **characterized in** that said DHF parameter is the time, DT, from the occurrence of peak blood flow velocity (E) through the mitral valve to zero blood flow velocity therethrough.

20. The method according to claim 19, **characterized in** that to determine DT the mitral blood flow velocity is extrapolated to zero, if zero velocity is not obtained before atrial contraction.

21. The method according to claim 20, **characterized in** that the time derivative of the blood flow velocity through the mitral valve shortly after said blood flow peak velocity (E) is determined for use for linearly extrapolating the blood flow velocity to zero.

22. The method according to claim 18, **characterized in** that said DHF parameter is the isovolumic relaxation time, IVRT,

5 23. The method according to any of the claims 19 – 22, **characterized in** that IEGM is measured for determining DT and/or IVRT.

24. The method according to any of the claims 19 – 23, **characterized in** that an impedance in the patient 's heart is measured for determining DT and/or IVRT

10

25. The method according to any of the claims 18 – 24, **characterized in** that said time length is determined at predetermined time intervals and stored.

15

26. The method according to any of the claims 18 – 24, **characterized in** that changes in said time length are determined and stored.

---

20

25

30

## ABSTRACT

An implantable medical apparatus for detecting diastolic heart failure, DHF, comprises a DHF determining device for determining at least one DHF parameter for detecting a DHF state of the heart of a patient. The DHF determining device 5 comprises a means for determining, as said DHF parameter, the time length (DT,IVRT) of a predetermined phase of diastole. A pacemaker comprises such an apparatus and control means for optimising pacing therapy and pacemaker settings depending on the determined time length. A corresponding method of detecting diastolic heart failure, DHF, comprises the step of determining at least one DHF 10 parameter for detecting a DHF state of the heart of a patient. This step comprises determining, as said DHF parameter, the time length (DT,IVRT) of a predetermined phase of diastole.


*a**b*

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6